Samsung Biologics, a popular contract development and manufacturing organisation (CDMO), has declared that Samsung Biologics America, a fully owned U.S subsidiary, has signed a definitive deal to procure full Human Genome Sciences (HGS) from GSK. This smart strategy will protect Samsung Biologic’s first ever US situated manufacturing site. As the site is a meaningful expansion of the company’s presence globally, it's also a long-standing dedication by the company towards the U.S. sector.
At Rockville, Maryland, the facility is located in the middle of one of the major U.S. bioclusters and surrounds two cGMP manufacturing plants with the merger of 60,000 liters of medicinal substances. This backs commercial and clinical production from both small and large scales. The previous products will stay in the manufacturing at the site, while Samsung intends to make new investments to upgrade technology and extend the site’s potential to serve contribution towards the U.S. supply chain for crucial biologic medicines.
According to the terms of the agreement, with the closing expected at the end of Q1 of 2026, Samsung Biologics will obtain the Rockville assets for a worth of USD 280 million. Samsung will maintain its 500 employees in its workforce at the site to continue the operations and maintain stability. By unifying this facility into our worldwide network, the company will deliver clients a multi-site option in Korea and the U.S. for smoothness and flexibility to provide effective therapeutics to American patients.
Samsung Biologics has developed the best track record of construction and operational endeavour with its on-time completion of robust Bio Campus 1 and 2. The company has currently fixed the land to build its Bio Campus 3 that will include manufacturing programs and distinct R&D for new modalities. Along with the 785,000 liters of potential throughout the five plants, which is the industry’s popular capacity, the company will be moving ahead to modernise its variant portfolio.
The portfolio that bridges antibody-drug conjugates (ADCs), Mrna, next-generation therapies, monoclonal antibodies and organoid-based services. CEO and President of Samsung Biologics, John Rim, said, “This acquisition exemplifies our never-ending determination to advance global healthcare and strengthen our manufacturing ability in the U.S. The investment will allow us to intensify our partnership with state, local and federal stakeholders to provide excellence to our partners and customers, and also serve a stable and effective supply of life-saving therapeutics.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
